4 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 4 |
Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy REGN-2Cat, Freneslerbart, Mevonlerbart - Allergic Conjunctivitis | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 570 | 2026-07-31 | 2026-08-12 |
| An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED Cenegermin, Vehicle - Persistent Corneal Epithelial Defect | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 150 | 2026-06-02 | 2026-10-07 |
| 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion, 0.1% Cyclosporin A cationic ophthalmic emulsion - Vernal Keratoconjunctivitis | Phase 3 | Recruiting | The University of Hong Kong | 94 | 2026-02-09 | 2026-04-30 |
| Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis Fusidic Acid 1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Recruiting | Baxis Pharmaceuticals, Inc. | 400 | 2025-03-21 | 2026-03-17 |
Conjunctivitis, Allergic (3) · Bacterial Infections (1) · Conjunctival Diseases (1) · Conjunctivitis, Bacterial (1) · Dry Eye Syndromes (1) · Eye Diseases (1) · Eye Infections (1) · Eye Infections, Bacterial (1) · Infections (1)
Conjunctival Diseases (3) · Eye Diseases (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Bacterial Infections and Mycoses (1) · Lacrimal Apparatus Diseases (1)
cenegermin (1)
Baxis Pharmaceuticals, Inc. (1) · Dompé Farmaceutici S.p.A (1) · Regeneron Pharmaceuticals (1) · The University of Hong Kong (1)
United States (3) · Argentina (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Kendrick Co Shih (1)
2025 (1)